Disclaimer: Florin|Roebig is no longer accepting claims against Zantac for Acute Lymphoblastic Leukemia (ALL). This content is for informational purposes.
On April 1, 2020, the U.S. Food and Drug Administration (FDA) released an official statement requesting that all manufacturers of Zantac (ranitidine) products remove their drugs from the U.S. drug market, stating the drugs may contain a potentially cancerous chemical known as NDMA.
This statement follows previous statements made by the FDA since November 2019, updating healthcare providers and patients on the discovery of dangerous levels of NDMA in certain Zantac and ranitidine products.
This discovery has become the basis of thousands of Zantac lawsuits filed nationwide by individuals who developed cancer, or lost a loved one to cancer, after regularly taking Zantac for years.
One of the types of cancer being investigated for a potential link to Zantac use is acute lymphoblastic leukemia (ALL), which is a cancer of the blood and bone marrow.
If you or a loved one has developed acute lymphoblastic leukemia (ALL) after taking Zantac for a health condition, our top-rated drug lawsuit lawyers may be able to help you file a lawsuit against Zantac drugmakers to recover compensation.
About Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is a type of cancer that affects cells in the blood and bone marrow. Compared to other forms of leukemia, ALL can develop very rapidly and become fatal within as little as a few months if left untreated.
According to the American Cancer Society, ALL develops in lymphocytes, which are a type of white blood cell. People develop cancer when these or other types of cells in the body grow out of control.
This type of leukemia initially develops in the bone marrow and from there can invade the blood as well as spread to other areas of the body. ALL is the most common type of cancer in children, with children under 5 at the highest risk for developing ALL.
This type of leukemia accounts for about one percent of total cancer diagnoses in the U.S., with four in 10 cases occurring in adults. The prognosis for individuals with ALL who receive treatment is most promising in children, with the majority of ALL deaths occurring in adults.
Cause Of Acute Lymphoblastic Leukemia
The primary cause of ALL is believed to be tied to certain gene mutations, although the cause of these mutations is still being investigated. Most cases of ALL are not inherited.
Acute lymphoblastic leukemia initially develops through abnormal cell production, in which bone marrow cells continue growing and dividing—contrary to the activity of healthy cells— leading to the production of lymphoblasts.
There is no known method of preventing the development of ALL at this time. Like most cancers, the main treatment for ALL is chemotherapy. Other types of treatment include immunotherapy and specific drugs believed to target the gene changes seen with ALL.
Symptoms of acute lymphoblastic leukemia (ALL) include:
- bone pain
- bleeding from the gums
- shortness of breath
- long-lasting or recurrent infections
- heavy bleeding from the gums, nose, or during menstrual cycles
What’s The Link Between Acute Lymphoblastic Leukemia (ALL) and Zantac?
For decades, Zantac has been one of the top-selling drugs worldwide for treating health conditions such as heartburn, gastroesophageal reflux disease (GERD), and ulcers. Millions of individuals in the U.S. are believed to take or receive a prescription for Zantac each year.
In November 2019, the FDA released an official statement reporting NDMA impurities in certain lots of Zantac and ranitidine drugs. Zantac is a popular brand name for drugs containing the active ingredient, ranitidine.
N-Nitrosodimethylamine (NDMA) is a cancerous chemical that has been linked to various types of cancer, including cancer of the stomach, kidneys, liver, bladder, as well as cancer of the blood. This makes ALL one of the primary types of cancer being investigated for an association to Zantac use.
Since this initial discovery of NDMA in Zantac, various research laboratories have conducted testing on Zantac products to test NDMA levels, including those of their primary pharmaceutical manufacturers.
Valisure, the online pharmacy that first identified the NDMA in ranitidine, found levels of NDMA in their drugs that were up to 31,000 times higher than the FDA-recommended acceptable daily intake.
Drug testing by the FDA has found lower levels of NDMA in Zantac. However, in their latest statement, the federal agency stated that additional investigation into the problem has revealed that the amount of NDMA in ranitidine may increase over time, making older products more likely to contain higher amounts of NDMA.
This discovery is the primary reason underlying their latest decision to request the removal of all Zantac products from U.S. pharmacy and store shelves.
How Taking Zantac May Increase Risk Of Acute Lymphoblastic Leukemia
The risk for developing cancers like ALL after taking Zantac is still being investigated by agencies such as the FDA and World Health Organization (WHO).
According to Harvard Medical School professor, Joshua Gagne, the potential dangers of the NDMA found in Zantac are more likely to impact individuals who have taken Zantac regularly (at least two or three times per week) for an extended amount of time. Taking Zantac once or twice for acid reflux is unlikely to significantly increase a person’s risk for cancer.
Unfortunately, Zantac is frequently used long-term, as a drug believed to be effective for the long-term treatment of gastric reflux conditions and stomach ulcers. It is available over-the-counter and by prescription.
This means that many of the people who have taken Zantac are likely long-term users of the drug, which could put them at risk for the dangers of NDMA.
Signs of NDMA overexposure and potential dangers include:
- stomach pain
- nausea and vomiting
- reduced function of the liver, kidneys, and lungs
- enlarged liver
If you’ve taken Zantac regularly for years and have been affected by the latest FDA recalls, consider talking to your doctor about alternative treatment options. It may not be safe for you to continue taking Zantac or ranitidine at this time.
Our Featured Case Results
What To Do About An Acute Lymphoblastic Leukemia Diagnosis After Taking Zantac
The American Cancer Society estimates there will be 6,150 new cases of acute lymphoblastic leukemia diagnosed in the U.S. in 2020.
Although making up only a small percentage of total cancer diagnoses in the U.S., ALL is one of the primary types of cancer believed to be linked to overexposure to NDMA, the cancerous chemical found in Zantac products.
If you or a loved one has been diagnosed with ALL after taking Zantac regularly for a health condition, consider taking these steps:
Consult Your Doctor
Before adjusting your dosage of Zantac, contact your doctor as soon as possible to discuss what course of treatment is most appropriate for your health needs.
Your doctor can recommend a personalized course of treatment based on your medical history and other personal factors that may affect the type of treatment you’ll need moving forward.
If you’ve been diagnosed with ALL, your treatment team may be able to assess whether it’s possible your use of Zantac caused or influenced your development of ALL. If you’re concerned about developing ALL, your doctor may be able to recommend testing to determine your risk for ALL and other health problems linked to the NDMA in Zantac.
Contact A Zantac Attorney
Thousands of lawsuits across the U.S. have been filed against the primary manufacturers of Zantac products, including defendants Sanofi, Boehringer Ingelheim, and Pfizer among others.
Depending on the nature of your relationship to Zantac, an experienced lawyer who has been following the latest updates on Zantac cancer lawsuits may be able to help you file a lawsuit against these companies on the basis of product liability, personal injury, or wrongful death.
Although many of the people suing Zantac drugmakers are people who have developed cancer after taking Zantac, lawsuits have also been filed by surviving family members of loved ones who developed cancer and later died after taking Zantac for an unrelated health condition.
Zantac drugmakers are currently facing class action lawsuits—which represent groups of people similarly harmed by dangerous drugs—and multidistrict litigation lawsuits, which are individual lawsuits grouped together for an expedited litigation process.
If you or a loved one has taken Zantac long-term and later been diagnosed with ALL, the Zantac cancer lawyers of Florin|Roebig can assess your eligibility to take legal action and provide you with an overview of your legal options.
We Are Nationally Awarded Lawyers
Find Help Filing A Zantac Lawsuit Against Drugmakers
At Florin|Roebig, our Zantac cancer lawyers have been diligently following the latest updates on the latest Zantac lawsuits and are representing individuals who wish to sue the drugmakers for unlawfully exposing them to the dangerous NDMA found in their drugs.
If you or a loved one has been diagnosed with ALL after taking Zantac, our lawyers are ready to hear your story. We offer new clients a no-obligation case evaluation, free of charge. Don’t wait to learn what we may be able to do for you.
Contact the offices of Florin|Roebig today to determine your eligibility for joining a Zantac class action or multidistrict lawsuit against Zantac drug manufacturers.